Skip to main content

Table 1 Patient characteristics and demographics

From: Eosinophils in anti-neutrophil cytoplasmic antibody associated vasculitis

  All patients (n = 98) Remissiona (n = 76) Active diseasea (n = 22)
Age, years, median (range) 53 (19–85) 68 (24–84) 63 (19–85)
Disease duration, years, median (range) 6 (0–50) 7 (0–50) 0.5 (0–25)
GPA, %, (n) 76 (74) 74 (56) 82 (18)
MPA, %, (n) 24 (24) 26 (20) 18 (4)
PR3-ANCA, %, (n) 63 (62) 61 (46) 73 (16)
MPO-ANCA, %, (n) 30 (30) 32 (24) 27 (6)
ANCA negativeb 5 (5) 5 (4) 0 (0)
BVAS3, median (range) 0 (0–16) 0 (0–0) 5 (1–16)
Leukocytes, 109/L, median (range)c 6.4 (3–13.7) 6.2 (3.2–13.7) 7.9 (3–12)
p-creatinine, μmol/L, median (range) 103 (54–805) 98 (61–635) 154 (54–805)
p-CRP, mg/L, median (range) 2.9 (< 0.6–92) 2.6 (< 0.6–27) 5.7 (< 0.6–92)
Treatment
 Prednisone, %, median dose of treated 59 (6.25 mg/d) 53 (5 mg/d) 82 (17.5 mg/d)
 Azathioprine, % (n) 28 (27) 32 (24) 14 (3)
 Mycophenolate, % (n) 8 (8) 11 (8) 0 (0)
 Rituximab, % (n) 20 (20) 21 (16) 18 (4)
 Methotrexate, % (n) 14 (14) 13 (10) 18 (4)
 Cyklophosphamide, % (n) 13 (13) 7 (5) 36 (8)
 No current treatment, % (n) 12 (12) 14 (11) 9 (3)
  1. BVAS3 Birmingham Vasculitis Activity Score version 3, GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis, MPO myeloperoxidase, ANCA anti-neutrophil cytoplasmic antibodies, PR3 proteinase 3, CRP C-reactive protein
  2. aPatients in remission have BVAS3 = 0 and patients with active disease BVAS3 ≥ 1
  3. bANCA data is missing on one patient and one was double positive
  4. cReference range 3.5–8.8 109/L. Treatment at the time of sampling except for Rituximab that is reported as given at any time during the disease